Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Apr;113(4):708-18.
doi: 10.1160/TH14-09-0731. Epub 2014 Dec 11.

VWF excess and ADAMTS13 deficiency: a unifying pathomechanism linking inflammation to thrombosis in DIC, malaria, and TTP

Affiliations
Review

VWF excess and ADAMTS13 deficiency: a unifying pathomechanism linking inflammation to thrombosis in DIC, malaria, and TTP

Michael Schwameis et al. Thromb Haemost. 2015 Apr.

Abstract

Absent or severely diminished activity of ADAMTS13 (A Disintegrin And Metalloprotease with a ThromboSpondin type 1 motif, member 13) resulting in the intravascular persistence and accumulation of highly thrombogenic ultra large von Willebrand factor (UL-VWF) multimers is the pathophysiological mechanism underlying thrombotic thrombocytopenic purpura. Reduced VWF-cleaving protease levels, however, are not uniquely restricted to primary thrombotic microangiopathy (TMA), e. g. thrombotic thrombocytopenic purpura, but also occur in other life-threatening thrombocytopenic conditions: severely decreased ADAMTS13 activity is seen in severe sepsis, disseminated intravascular coagulation (DIC) and complicated malarial infection. The clinical relevance of these secondary thrombotic microangiopathies is increasingly recognised, but its therapeutic implications have not yet been determined. The presence of a secondary TMA in certain diseases may define patient groups which possibly could benefit from ADAMTS13 replacement or a VWF-targeting therapy. This short-review focuses on the role of UL-VWF multimers in secondary TMA and discusses the potential of investigational therapies as candidates for the treatment of TTP. In conclusion, prospective clinical trials on the effectiveness of protease replacementin vivo seem reasonable. Carefully selected patients with secondary TMA may benefit from therapies primarily intended for the use in patients with TTP.

Keywords: ADAMTS13; DIC; TTP; VWF; malaria; sepsis.

PubMed Disclaimer

Figures

Figure1
Figure1. Entrapment of platelets and erythrocytes by uncleaved von Willebrand factor multimers under shear flow causing microvessel occlusion in (A) malarial infection and (B) TTP
(A) Microvessel obstruction by infected red cells is a crucial event in malarial coagulopathy and determines disease severity. Acutely exocytosed ultra large VWF strings attached to the endothelium thereby play a critical role by spontaneously binding large numbers of platelets, which finally facilitate endothelial adhesion and sequestration of red blood cells infected with plasmodia by providing the essential CD36-expressing surfaces. (B) In TTP, strand-shaped hyper-reactive VWF-multimers with a length exceeding 0,2mm spontaneously bind, activate and aggregate platelets leading to widespread depositions of microvessel-occlusive platelet-rich clots. Red blood cells passing through this UL-VWF-platelet meshwork get fragmented into schistocytes and helmet cells. Detaching and cleaving of UL-VWF strings through ADAMTS13 replenishment may interrupt microthrombus formation, re-establish vessel patency and improve organ function. Freely adapted from José A. López (101).

Similar articles

Cited by

References

    1. Ruggeri ZM, Ware J. von Willebrand factor. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 1993;7(2):308–16. - PubMed
    1. Lenting PJ, Casari C, Christophe OD, et al. von Willebrand factor: the old, the new and the unknown. Journal of thrombosis and haemostasis : JTH. 2012;10(12):2428–37. - PubMed
    1. Vischer UM, Barth H, Wollheim CB. Regulated von Willebrand factor secretion is associated with agonist-specific patterns of cytoskeletal remodeling in cultured endothelial cells. Arteriosclerosis, thrombosis, and vascular biology. 2000;20(3):883–91. - PubMed
    1. Ribes JA, Francis CW, Wagner DD. Fibrin induces release of von Willebrand factor from endothelial cells. The Journal of clinical investigation. 1987;79(1):117–23. - PMC - PubMed
    1. Bernardo A, Ball C, Nolasco L, et al. Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow. Blood. 2004;104(1):100–6. - PubMed

Publication types

MeSH terms